- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05637450
Fish Protein Supplementation and Sarcopenia Outcomes in Carehomes (SARCO_CARE)
Blue Whiting Protein Hydrolysates and Sarcopenia Outcomes in Older Adults Residing in Residential Care Facilities (SARCO_CARE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Sarcopenia is a progressive and generalised skeletal muscle disorder involving the accelerated loss of muscle mass and function that is associated with increase adverse outcomes including falls, functional decline, frailty and mortality. Diet, specifically protein has been proposed to have a role in the prevention and treatment of muscle loss in the older adult population nevertheless there is paucity of research on the effect of protein supplementation on lean body mass and other clinical outcomes in older adults, and especially those in residential care where the prevalence of muscle loss and weakness is reported to be high This 2-arm parallel, double-blind, randomised, controlled dietary supplement human intervention study aims to investigate the effect of consuming 12.5g (twice daily) Blue Whiting Protein Hydrolysates daily for 6 weeks on whole body lean mass tissue and measures of muscle strength and functionality in free living community dwelling older adults. A total of 184 participants (92 per group) is required based on a previous study by Norton et al (2015) Participants will be stratified by age, gender and BMI and randomly allocated to consume two sachets of either the BWPH powder daily (12.5g at lunch and dinner (Total 25g)), (mixed with an everyday food / drink product (provided by Ulster University) or an isocalorific maltodextrin citrus flavoured powder (Control) (mixed with an everyday food / drink product).
Assessments to be undertaken pre and post intervention include; body composition including lean mass tissue by Tanita body composition monitor, hand grip strength, a 'timed get up and go' test, chair stand test, blood pressure measurements, a habitual dietary intake questionnaire, quality of life questionnaire, SARC-F (screening tool for sarcopenia) and an MNA questionnaire (mini nutritional assessment). A trained phlebotomist will obtain a 40ml max blood sample from each participant pre and post intervention. Blood samples will be used to measure markers associated with sarcopenia (serum 25(OH)D, pro inflammatory cytokine profile, full lipid profiles and kidney and liver profiles).
All researchers taking physical measurements will be trained in the correct procedure and will follow a standardised protocol whilst taking all measurements. All physical measurements will be taken with the participant wearing light clothing (without footwear). Measurements will be taken pre- and post-intervention unless otherwise stated. All measurements for each participant will be recorded on a single data collection sheet.
Height and weight will be measured to determine BMI (kg/m2). Standing height (m) will be measured (pre-intervention only) to the nearest 0.5cm using a calibrated stadiometer (SECA, Model 220, Germany). Body weight (kg) will be recorded without footwear or heavy clothing and measured to the nearest 0.1kg using portable scales (Seca; Brosch Direct Ltd, Peterborough, UK).
A Tanita body composition monitor will use bioelectrical impedance analysis to estimate body composition in all participants, except in those with pacemakers because of the electrical current used.
Blood pressure will be measured using an Omron 705CP electronic blood pressure monitor (Medisave, Dorset, UK). A reading will be taken from both arms of each participant, and the arm with the highest reading for each individual will subsequently be used as the reference arm. A mean of two blood pressure readings (taken at least 10 minutes apart while the subject is seated and at-rest) will be taken from the same reference arm at all appointments. A third measurement will be taken if the first two measurements deviate by more than 10%.
Hand grip dynamometry will be used to assess grip strength (kg) as a measure of upper body muscle function and will be measured on the non-dominant side three times. In a standing position, with arms at their side (not touching the body and keeping elbows slightly bent), the participant will be asked to hold the device and grip as tightly as possible whilst raising their arm out to the side, taking care to only squeeze once for each measurement. There will be a 10-20 second rest between measurements.
A timed up & go test will be conducted to test basic mobility (Podsiadlo & Richardson, 1991). A 3 metre distance will be identified and the participant will be asked to stand up from a chair, walk at a normal pace to the line on the floor which is 3 metres from the chair, turn, walk back to the chair at normal pace and sit down again. The time taken to do this will be recorded. A trained researcher will explain the exact procedure to the participant.
A chair stand test will be conducted to assess functional fitness. Participants will be instructed to perform five rises with arms crossed resting hands on their shoulders, moving from a seated position to a stand position. The amount of time spent to perform the test will be reported.
The planned statistical analysis will be conducted using the Statistical Package for the Social Sciences (SPSS) for Windows version 24.0 (SPSS Inc, Chicago, IL, USA). Intention to treat analysis will be used. Descriptive statistics will be used to present characteristics pre- and post- intervention. Comparisons will be made (ANCOVA) between the intervention group and control group over time.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: • Philip J Allsopp
- Phone Number: +442870123125
- Email: pj.allsopp@ulster.ac.uk
Study Contact Backup
- Name: Mary M Slevin
- Phone Number: +44870123041
- Email: mm.slevin@ulster.ac.uk
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Individuals residing in a residential care facility
- Willing to participate in the study
- Without major cognitive impairment
- Not regularly taking protein supplements
- Not at end-of-life stage
Exclusion Criteria:
- At end-of-life stage.
- Major cognitive impairment
- Exclusively receiving enteral or parenteral nutrition
- Food allergy or intolerance that would prevent consumption of the study supplement (e.g. fish)
- Currently taking any protein supplement
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fish protein supplement
Blue Whiting Protein Hydrolysate
|
25g Blue Whiting Protein Hydrolysates mixed with an everyday food / drink product daily for 6 weeks
|
Placebo Comparator: Placebo
Isocalorific Maltodextrin Citrus Flavoured Powder
|
Isocalorific maltodextrin citrus flavoured powder mixed with an everyday food / drink product for 6 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lean mass
Time Frame: Change over 6 weeks
|
Assessed via Tanita body composition monitor
|
Change over 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Muscle strength
Time Frame: Change over 6 weeks
|
Measured via hand grip dynamometry
|
Change over 6 weeks
|
Muscle functionality
Time Frame: Change over 6 weeks
|
Measured via hand grip dynamometry
|
Change over 6 weeks
|
Mobility
Time Frame: Change over 6 weeks
|
Assessed through timed get up and go test (time to walk 3 metres)
|
Change over 6 weeks
|
Mobility
Time Frame: Change over 6 weeks
|
Assessed through chair stand test
|
Change over 6 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
General clinical chemistry
Time Frame: Change over 6 weeks
|
Full lipid profile (Total, HDL & triacylglycerols) measured photometrically on an automatic analyser.
LDL will be calculated by the Friedewald formula
|
Change over 6 weeks
|
General clinical chemistry
Time Frame: Change over 6 weeks
|
Vitamin B status
|
Change over 6 weeks
|
General clinical chemistry
Time Frame: Change over 6 weeks
|
Vitamin D status
|
Change over 6 weeks
|
General clinical chemistry
Time Frame: Change over 6 weeks
|
Pro inflammatory markers (Human panel 1) measured on Meso Scale Discovery
|
Change over 6 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22/NI/0108
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcopenia
-
University of Texas at AustinNot yet recruitingExercise Training and SarcopeniaUnited States
-
Centre Hospitalier Universitaire DijonCompleted
-
Creighton UniversityUniversity of NebraskaRecruiting
-
University Hospital, CaenCompleted
-
University of NottinghamUniversity of OxfordRecruitingMuscle Atrophy | Age-Related SarcopeniaUnited Kingdom
-
Tufts UniversityNational Institute on Aging (NIA)CompletedMuscle Loss | Age-Related SarcopeniaUnited States
-
China Medical University HospitalCompleted
-
King's College LondonCo-sponsor: Guy's and St Thomas' NHS Foundation TrustCompletedFrailty | Sarcopenia | Age-Related SarcopeniaUnited Kingdom
-
Norwegian School of Sport SciencesOslo University HospitalNot yet recruitingHealthy Aging | Testosterone Deficiency | Age-Related Sarcopenia
-
Ningbo Medical Center Lihuili HospitalCompletedHemodialysis Patients With SarcopeniaChina
Clinical Trials on Blue Whiting Protein Hydrolysate
-
University of BergenCompletedInflammation | Muscle Weakness | Aging | Muscle Loss | Blood Sugar; High
-
Helse Møre og Romsdal HFHaukeland University HospitalCompletedHealthy VolunteersNorway
-
Natural Immune Systems IncRecruiting
-
BioActorCompletedMuscle Strength Recovery
-
Atlantia Food Clinical TrialsTerminated
-
Abyss IngredientsUniversity Hospital, Bordeaux; Laboratoire Nutrition et Neurobiologie intégréeCompletedMemory Impairment | Age-related Cognitive DeclineFrance
-
Stanford UniversityNot yet recruitingUlcerative ColitisUnited States
-
Molde University CollegeCompleted
-
Chung Shan Medical UniversityNational Taichung University of EducationCompleted
-
Maastricht University Medical CenterCompletedType 2 Diabetes Mellitus | Impaired Glucose Tolerance | Dietary Modification | Arterial StiffnessNetherlands